Question 1
Which company is developing its own version of semaglutide-based drugs to compete in the market?
Question 2
What financial barrier is associated with semaglutide-based obesity treatments?
Question 3
How does semaglutide help in reducing food intake?
Question 4
Which company originally developed semaglutide-based drugs like Wagavi?
Question 5
What is a primary concern of semaglutide drugs being misused?
Question 6
What is the active ingredient in new obesity treatments like Wagavi and Ozempek?
Question 7
What major area is anticipated to see growth due to new obesity treatments?
Question 8
Why is the obesity treatment market projected to exceed $50 billion by the end of the decade?
Question 9
What is the mechanism of action for GLP-1 receptor agonists?
Question 10
What has contributed to the growing popularity of semaglutide-based obesity treatments?
Question 11
What potential downside is associated with long-term use of these obesity drugs?
Question 12
Which side effects are commonly associated with GLP-1 receptor agonists?
Question 13
GLP-1 receptor agonists were originally developed for the treatment of which condition?
Question 14
What is a concern related to the off-label use of semaglutide drugs?
Question 15
What impact might new obesity drugs have on the body positivity movement?